COMMON STOCK PURCHASE WARRANT BLUE WATER VACCINES, INC.Common Stock Purchase Warrant • January 6th, 2022 • Blue Water Vaccines Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [_____], 20__1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Blue Water Vaccines, Inc., a Delaware corporation (the “Company”), up to [___] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’
BLUE WATER VACCINES, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Warrant Agent Warrant Agency Agreement Dated as of [ ] __, 2022 WARRANT AGENCY AGREEMENTWarrant Agency Agreement • January 6th, 2022 • Blue Water Vaccines Inc. • Pharmaceutical preparations • California
WARRANT AGENCY AGREEMENT, dated as of [ ] __, 2022 (“Agreement”), between Blue Water Vaccines, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Continental Stock Transfer & Trust Company., a corporation organized under the laws of [ ] (the “Warrant Agent”).
EMPLOYMENT AGREEMENTEmployment Agreement • January 6th, 2022 • Blue Water Vaccines Inc. • Pharmaceutical preparations • Ohio
This EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of [•], 2022 by and between Blue Water Vaccines, Inc., a Delaware corporation (the “Company”) and Erin Henderson (“Executive”).
